That's wonderful! Are you finding it tolerable?

I just started a clinical trial of a very similar drug (also an anti-HER2 antibody-drug conjugate with an irinotecan-like payload, but from a different company). My tumor had a +1 IHC score for HER2, which the original report called "negative", but apparently these "HER2 low" tumors often do respond to these drugs.

It remains to be seen whether my tumors respond. But I'm finding the drug to be very tolerable so far (knock on wood).